Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia

Expert Rev Hematol. 2024 Apr-May;17(4-5):103-106. doi: 10.1080/17474086.2024.2347303. Epub 2024 May 3.

Authors

Håkon Reikvam^{1

2}, Richard Dillon³

Affiliations

¹ K.G. Jebsen Center for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway.
² Department of Medicine, Haukeland University Hospital, Bergen, Norway.
³ Department of Medical and Molecular Genetics, King's College, Guy's and St Thomas' NHS Foundation Trust, London, UK.

PMID: 38654593
DOI: 10.1080/17474086.2024.2347303

No abstract available

Keywords: Acute myelogenous leukemia; FLT3 mutation; NGS; PCR; flow-cytometry; measurable residual disease.

Publication types

Editorial

MeSH terms

Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / therapy
Mutation*
Neoplasm, Residual*
fms-Like Tyrosine Kinase 3* / genetics
fms-Like Tyrosine Kinase 3* / metabolism